Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19

Paisan Ruamviboonsuk, MD*, Timothy Y. Y. Lai, MD, FRCOphth†, Andrew Chang, PhD, FRANZCO‡, Chi-Chun Lai, MD§, William F Mieler, MD¶, and Dennis S. C. Lam, MD||**
for Asia-Pacific Vitreo-Retina Society

Abstract: The proposed doses of chloroquine (CQ) and hydroxychloroquine (HCQ) for treatment of COVID-19 (1000 mg/day for 10 days, CQ; 800 mg first day then 400 mg/day for 5 days, HCQ) in many guidelines worldwide, are considerably higher than the maximum recommended daily safe doses of both agents (≤2.3 mg/kg/day, CQ; ≤3.0 mg/kg/day, HCQ) for development of retinal toxicity. Irreversible retinal damage can occur if exposure to the safe doses is >5 years. It is not known whether exposure to high doses over a short period of time can also cause the damage. We recommend that before prescribing CQ or HCQ, history of ocular disease should be obtained to avoid the prescription if appropriate. If either agent is to be used, routine baseline ocular examination is not absolutely necessary. Patients who do not have ocular disease should also be informed about the potential risk of retinal toxicity. Both agents, however, have not yet been proven to be beneficial to COVID-19.

Key Words: chloroquine, coronavirus, hydroxychloroquine, maculopathy, retinopathy

From the *Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand; †Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China; ‡Sydney Eye Hospital, Sydney University, Sydney, NSW, Australia; §Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan; ¶Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; ||International Eye Research Institute of the Chinese University of Hong Kong (Shenzhen), Shenzhen, China; and |||C-MER Dennis Lam Eye Centre, C-MER International Eye Care Group Limited, Hong Kong SAR, China.

Submitted February 9, 2020; accepted March 31, 2020.
The authors have no conflicts of interest to declare.
Correspondence: Paisan Ruamviboonsuk, Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
10400. E-mail: paisan.trc@gmail.com, Timothy Lai, M.D., FRCOphth, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China 999077. E-mail: tyylai@cuhk.edu.hk.

This work was supported by grants from the National Natural Science Foundation of China (81670866), the National Key Research and Development Program of China (2018YFC0114000), and the National Key R&D Program of China (2018YFC1002900). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/APO.0000000000000289
Table 1. Comparison Between the Maximum Daily Safe Doses of Chloroquine and Hydroxychloroquine for Development of Retinal Toxicity and the Recommended Doses in COVID-19 Treatment Guidelines from Different Countries

<table>
<thead>
<tr>
<th>Dosing Regimen</th>
<th>Maximum Recommended Dosing Regimen</th>
<th>Daily Safe Dose for Retinal Toxicity</th>
<th>Maximum Recommended Daily Safe Dose for Retinal Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dutch Guideline</td>
<td>1000 mg/day for at least 5 days</td>
<td>2.3 mg/kg/day</td>
<td>Estimated global dose = 142.6 mg/day</td>
</tr>
<tr>
<td>Belgian Guideline</td>
<td>1000 mg/day for 10 days</td>
<td>900 mg Day 1, then 600 mg/day up to 5 days</td>
<td>Estimated global dose = 310 mg/day</td>
</tr>
<tr>
<td>Italian Guideline</td>
<td>1000 mg/day for 10 days</td>
<td>600 mg/day up to 5 days</td>
<td></td>
</tr>
<tr>
<td>Chinese Guideline</td>
<td>800 mg Day 1, then 400 mg/day for 5 days</td>
<td>800 mg Day 1, then 400 mg/day for 5 days</td>
<td></td>
</tr>
<tr>
<td>Thai Guideline</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

The estimated global doses are estimated according to the global average weight of adults (62 kg).17

In summary, the bottom line at the present time is that neither CQ nor HCQ has been proven to be effective in the treatment of COVID-19, although there is certainly a vast interest in its possible benefit. Further controlled clinical trial data will be necessary to help better address this issue. Despite the current situation of COVID-19 pandemic, many adverse effects of either CQ or HCQ should still be weighed against its potential benefit. For retinal toxicity, the risk of having irreversible retinal damage major risk factor is the use of higher than generally recommended dosage, although over a relatively short period of time, that is for about a week. There has not yet been a report on retinal toxicity associated with this kind of treatment. Nonetheless, it has been reported that retinal toxicity can develop even after <1 year of high dose of HCQ use (1000 mg daily) in an oncology trial.14

In this report, 2 of 7 patients who received the high dose of HCQ showed abnormalities of the macula on retinal imaging modalities and multifocal electoretinogram without visual symptoms. These patients did not have any known risk factors, such as renal disease, concomitant retinotoxic agents, or co-existing retinal disease. It is not known whether the retinal toxicity from high-dose CQ and HCQ is underreported in the literature due to suboptimal and nonuniform ocular screening methods.14

Both CQ and HCQ are known for their binding affinity with melanin in retinal pigment epithelium which can be a mechanism of the toxic effects. Both agents have also been shown to cause damage to the photoreceptor layer and outer nuclear layer of the retina, whereas CQ can cause damage to the inner retina as well. Light absorption and metabolism of cone cells may also play roles for the damages. These mechanisms may lead to clinically characteristic “bull’s eye” maculopathy after chronic exposure to both agents even in the safe dose.15 It is not known whether exposure to the high dose over a short period may also cause similar cellular damages as with the chronic exposure. Given that patients with COVID-19 who may require treatment are commonly older patients, it is possible that some may already have coexistent age-related macular degeneration. It is still not known whether the diseased macula would be more vulnerable to damage with exposure to the high dose of either CQ or HCQ even over a short duration.

Routine baseline ocular examination is not absolutely necessary for patients with COVID-19 who are undergoing treatment with CQ and HCQ but should be considered if manpower and expertise are available and extreme precautions should be taken during the examination. It is relevant, however, to take a history of ocular disease, particularly macular disease, in patients with COVID-19 who are older than 50 years before prescribing CQ or HCQ as treatment, to rule out age-related macular degeneration or other macular abnormalities. Coexistent retinal pathology is listed as a contraindication of using CQ and HCQ in patients with COVID-19 in the treatment guideline of Belgium.7 As treatment with CQ or HCQ is not yet proven to be beneficial, but instead can be harmful,16 in COVID-19, choosing other options of treatment in this group of patients with the preexisting disease may be more appropriate. For patients in whom CQ or HCQ is still considered as a treatment option, the potential benefits and risks of retinal toxicity and other systemic complications shall be thoroughly discussed with patients and well documented on written consent form before the treatment or trial of CQ or HCQ. Following recovery from COVID-19 with the treatment using CQ or HCQ, the patients should also be informed to visit ophthalmologists if they encounter any abnormal visual symptoms.

In summary, the bottom line at the present time is that neither CQ nor HCQ has been proven to be effective in the treatment of COVID-19, although there is certainly a vast interest in its possible benefit. Further controlled clinical trial data will be necessary to help better address this issue. Despite the current situation of COVID-19 pandemic, many adverse effects of either CQ or HCQ should still be weighed against its potential benefit. For retinal toxicity, the risk of having irreversible retinal damage...
and visual loss may outweigh the unproven benefit of both agents in some patients. Detecting the risk is easy. It can be done by simply taking a history of previous or co-existing ocular disease from the patients, then other options of treatment should be considered if appropriate.

ACKNOWLEDGEMENT

The authors acknowledge Varis Ruamviboonsuk, MD, in assisting manuscript preparation.

REFERENCES


